<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03129360</url>
  </required_header>
  <id_info>
    <org_study_id>17-00266</org_study_id>
    <nct_id>NCT03129360</nct_id>
  </id_info>
  <brief_title>Levetiracetam in Early Psychosis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Trial Investigating the Effects of Levetiracetam in Early Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to establish target engagement and identify an effective dose the investigators will&#xD;
      conduct a placebo-controlled single-dose parallel group trial of levetiracetam 185 mg and 500&#xD;
      mg in 24 medication-naïve early psychosis (EP) patients, measuring hippocampal activity by&#xD;
      pulsed arterial spin labelling (ASL) pre-dose and 2 hours post-dose. The lower dose is&#xD;
      calculated to achieve blood levels within the range that were associated with reduced&#xD;
      hippocampal activity and improved cognition in patients with mild cognitive impairment; the&#xD;
      higher dose is a typical antiepileptic dose. Successful demonstration of target engagement&#xD;
      will be defined by an effect size of 0.5 or greater compared to placebo in reduction by&#xD;
      levetiracetam of hippocampal blood flow measured by ASL. The optimal dose will be defined by&#xD;
      maximal reduction of hippocampal perfusion in the absence of clinically-significant adverse&#xD;
      effects. The investigators will also study 8 healthy control subjects to verify that baseline&#xD;
      hippocampal blood flow is elevated in the sample of FEP subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">March 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 22, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial Spin Labeling (ASL)</measure>
    <time_frame>Before and 2 hours post-treatment.</time_frame>
    <description>Change in cerebral blood flow (CBF) as measured by ASL.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Psychosis</condition>
  <condition>Schizophrenia</condition>
  <condition>Schizo Affective Disorder</condition>
  <condition>Schizophreniform</condition>
  <arm_group>
    <arm_group_label>Levetiracetam 185 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 185mg of levetiracetam be administered orally to subjects. Subjects will undergo a 15-minute MRI scan using aterial spin labeling (ASL) before dosing and two hours post-dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levetiracetam 500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of 500mg of levetiracetam will be administered orally to subjects. Subjects will undergo a 15-minute MRI scan using aterial spin labeling (ASL) before dosing and two hours post-dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single dose of placebo will be administered orally to subjects. Subjects will undergo a 15-minute MRI scan using aterial spin labeling (ASL) before dosing and two hours post-dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>Levetiracetam is an atypical anticonvulsant that is frequently used in children and adults due to its superior tolerability, ease of use and excellent safety profile.</description>
    <arm_group_label>Levetiracetam 185 mg</arm_group_label>
    <arm_group_label>Levetiracetam 500mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females 16 to 35 years of age, inclusive, at time of informed consent&#xD;
&#xD;
          2. Must have experienced a first episode of non-affective psychosis within 5 years and&#xD;
             exhibit current psychosis, as defined by a score of ≥ 2 on one of the following&#xD;
             psychosis items on the BPRS: conceptual disorganization, suspiciousness,&#xD;
             hallucinations, unusual thought content, or grandiosity, for at least 4 days per week&#xD;
             for at least 4 weeks&#xD;
&#xD;
          3. Must have a diagnosis of either schizophrenia, schizoaffective disorder or&#xD;
             schizophreniform disorder as established by a Structured Clinical Interview for DSMIV&#xD;
             TR (SCID)&#xD;
&#xD;
          4. Must not have taken an oral antipsychotic medication within the past 4 weeks prior to&#xD;
             study enrollment or received a long acting injectable antipsychotic within 3 times the&#xD;
             dosing interval&#xD;
&#xD;
          5. If female and of childbearing potential, patients must:&#xD;
&#xD;
               1. Have a negative urine pregnancy test (all females regardless of childbearing&#xD;
                  potential will be required to submit a pregnancy test)&#xD;
&#xD;
               2. Not be nursing or planning a pregnancy for the duration of the study through 30&#xD;
                  days after the last dosing visit&#xD;
&#xD;
               3. Be abstinent or willing to use a reliable method of birth control from the&#xD;
                  screening visit and continue with the same method until termination from the&#xD;
                  study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current substance abuse or dependence for substances other than nicotine and THC&#xD;
             (i.e., alcohol, amphetamines, barbiturates)&#xD;
&#xD;
               1. A positive urine toxic screen (excluding THC, tricyclic antidepressants, or&#xD;
                  benzodiazepines (if prescribed))&#xD;
&#xD;
               2. Moderate or severe cannabis use disorder&#xD;
&#xD;
               3. Use of marijuana within the 72 hours prior to MRI scanning by self report&#xD;
&#xD;
          2. Diagnosis of major mood disorder or other Axis I disorder other than Schizophrenia,&#xD;
             Schizoaffective Disorder or Schizophreniform Disorder&#xD;
&#xD;
          3. Current suicidal ideation. Suicidal ideation with intent or plan (indicated by&#xD;
             affirmative answers to items 4 or 5 of the suicidal ideation section of the baseline&#xD;
             C-SSRS) in the 6 months prior to screening or subjects who represent a significant&#xD;
             risk of suicide in the opinion of the Principal Investigator and/or PhD or MD level&#xD;
             clinician completing screening visit&#xD;
&#xD;
          4. Pregnant, nursing or positive urine pregnancy test&#xD;
&#xD;
          5. Significant medical or neurological illness by history or physical exam including&#xD;
             seizure disorder, history of loss of consciousness related to head trauma or&#xD;
             developmental disorder including mental retardation&#xD;
&#xD;
          6. Metal implants, pacemaker, or other metal in the body or medicinal patch&#xD;
&#xD;
          7. History of claustrophobia&#xD;
&#xD;
          8. Currently taking any antipsychotic medication (within 4 weeks)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Goff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gillian Capichioni</last_name>
    <phone>917-628-0552</phone>
    <email>gillian.capichioni@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gillian Capichioni</last_name>
      <phone>917-628-0552</phone>
      <email>gillian.capichioni@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Donald Goff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 17, 2017</study_first_submitted>
  <study_first_submitted_qc>April 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Early Psychosis</keyword>
  <keyword>Levetiracetam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Mood Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

